Primmune Therapeutics Inc*, San Diego, California, will be awarded a $22,480,552 contract HDTRA1-24-C-0014 for “Oral broad spectrum antiviral TLR7 agonist for treatment of Lassa Fever”. This effort will support the Defense Threat Reduction Agency (DTRA) goal of providing counter weapons of mass destruction capabilities to meet current threats and challenges specifically through the development of a timely and effective biological defense solution for Lassa virus infection. The principal place of performance is San Diego, California. Work is expected to be completed by June 30, 2026. Fiscal 24 research and development funds in the amount of $845,610.00 are being obligated at the time of award. This award is the result of a competitive acquisition against the Broad Agency Announcement (BAA) HDTRA1-17-S-0002. SAM.gov was used to solicit proposals and 10 proposals were received. DTRA, DoDAAC HDTRA1, Fort Belvoir, Virginia, is the contracting activity.
Recommended
free preview